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Summary: This review, based on the current literature, considers the practical aspects of steroid radioimmunoassays.
The problems associated with the raising of specific antisera and their characterization are discussed. Features of assay
design, reliability criteria and practicability of radioimmunoassays for steroids are considered.
Radioimmunoassays für Steroide, eine Übersicht
Zusammenfassung: Die vorliegende Übersicht befaßt sich, basierend auf der einschlägigen jüngeren Literatur, mit der
praktischen Durchführung von Radioimmunoassays für Steroide. Die Möglichkeiten, spezifische Antiseren gegen
Steroide zu gewinnen und ihre Charakterisierung werden beschrieben. Die verschiedenen Aspekte des Aufbaus eines
Steroid-Radioimmunoassays, die Verläßlichkeitskriterien und die Praktikabilität werden diskutiert.
Introduction
The prime requirement on which the principle of
radioimmunoassay is based is the antiserum. Steroids
are not intrinsically antigenic because of their low mole-
cular weights, but they can be so rendered by coupling
to carrier proteins. Substances with molecular weights
lower than 1000 are non-irhmunogenic per se (1), and
for antibody formation it has been recommended that
substances with molecular weights lower than 3000












Attempts have been made to couple steroids to carrier
proteins since the early 1930's (3), but stable conjugates
capable of eliciting antibody formation in animals were
only synthesized some twenty years later (4, 5, 6, 7, 8).
*) This review is based on a lecture held at an International
Atomic Energy Agency Training Course on radioimmunoassay
techniques (Lima/Peru, October 1974).
2) Supported by the Deutsche Forschungsgemeinschaft.
Failure of some earlier attempts may have been due to
the biologically unstable ester bond that was used to
link the steroid to the protein (9). However, the anti-
sera developed were used primarily for the study of the
biological effects of steroids (10, 11). It remains an
irony of the history of endocrinology that radioimmuno-
assays for protein hormones were in use for almost
10 years (12) before the same principle was combined
with the steroid antisera (then also available for the
previous decade) to develop the first radioimmuno-
assay for a steroid (13, 14). From these beginnings the
number of assays available has increased rapidly, until
today it is possible to measure almost every steroid of
biological or pharmacological significance (tab. 1).
The greatest advantage of radioimmunoassay in the
measurement of steroids is the high sensitivity which
can be achieved, namely of the order of 10~12 g (l pg),
compared to the microgram quantities detected by
previous methods (tab. 2).
The essential requirements for a steroid radioimmuno-
assay are
(i) the antiserum,
(ii) the pure radiolabelled steroid,
(iii) some preliminary preparation of the biological
specimens in which the steroid is to be measured.
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The interrelation of these three factors is outlined in
figure 1. Each of these requirements will be discussed
in more detail, in order to provide an introduction to
and a review of the field of steroid radioimmunoassay.
Calculation of results




Steroids contain two types of oxygen functions (oxo
and hydroxyl groups) which can be used to link the
steroid moiety to a protein by stable peptide bond for-
mation. An intermediate derivative is first formed at
this reactive group; acyl chloride and hemisuccinate at
the hydroxyl group and oxime at the oxo group (4, 5,
15); thiol derivatives have also been used recently (16).
Coupling of this steroid derivative to the protein is achie-
ved either by a mixed anhydride reaction (4) or by
the carbodiimide method (17). The latter method has
been criticized because of the degree of cross-linking
produced within*and between the protein molecules
(18) and the mixed anhydride reaction seems to be the
preferred method. The coupling of dehydroepiandro-
sterone to bovine serum albumin via oxime formation
and using the mixed anhydride reaction is shown in
figure 2. Sites on each of the four rings (Α-D) of the
cyclopentanoperhydrophenanthrene skeleton can be
used for'coupling purposes. Figure 3 shows examples
of steroid conjugates, with coupling sites circled.
Carrier Proteins
.Bovine serum albumin is the most commonly used of
the carrier proteins. It is probably used because it is
readily available at a low cost. Since the antibody
response generally increases with the molecular weight
of the protein (1, 19), larger molecules such as thyro^
globulin, hem cyanin and polylysyl lysine have been
tried as carrier proteins. In our experience, antisera
from animals immunized with testosterone-3-hemo-
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Fig. 2. Conjugation of dehydroepiandrosteronc with a carrier
protein
cyanin were not superior to those immunized with
testosterone-3-bovine serum albumin.
In the final conjugate the molar ratio of steroid mole-
cules coupled per protein molecule is usually 8:1—30:1.
No convincing evidence has yet been produced which
Tab. 3. Immunization schedules for antiserum production
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footpads & subcutaneous 8%
intramuscular & subcutaneous 3%
without booster
intradermal 14%




















Fig. 3. Possible sites for conjugation with proteins on the steroid
skeleton (indicated by arrow), and concrete examples
(with coupling sites circled)
demonstrates that the actual steroid/protein ratio
influences the quality of the antiserum produced,
within these limits.
Immunization of Animals
All knowledge of the choice of animals, the route of
administration of immunogen and the use of adjuvants
apppears to be rather empirical. Although laboratory
aspects of radioimmunoassay have been much improved,
little effort has been made to rationalize immunization
procedures. It is not possible to ensure reproducibility
in the production of antisera when the immunization
schedules are purely arbitrary.
Choice of Animal
Although theoretically any species of the animal king-
dom could be used for immunization purposes, the
rabbit is the one most commonly chosen (tab. 3). The
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rabbit probably holds this favored position because it
has large ears with readily accessible vessels for drawing
blood and a blood volume large enough for antiserum
production for radioimmunoassay purposes, and it is
good natured. It is also easily kept under laboratory
conditions. Other animals, such as sheep, goats and
guinea pigs are also used, but they have the disadvantage
of either requiring special housing facilities or of being
too small to accumulate large volumes of antisera. Some
animals, rats and pigs for example, are very susceptible
to "adjuvant sickness" and are therefore not suitable
for antiserum production.
Routes for the Administration of Immunogen
All investigators unanimously useFra/m/'s adjuvant as
the emulsifying agent in which the immunogen is intro-
duced into the animal (20, 21). There is, however, a
large variation in the route of administration (22). All
possible routes of immunization, such as subcutaneous,
intradermal, intramuscular, intraperitoneal, thymus
transplanatation, into the lymph nodes or footpads,
have been used, either with or without booster injections
(tab. 3). Only immunization by the intradermal route
over multiple sitW on the back of the animal has been
successful without booster injections, and this schedule
has the further advantage that very small doses of the
immunogen are required (50-100 Mg per animal) (23,
24). High titers are achieved within 6 weeks of immuni-
zation. The development of titers produced by our
single, multiple-site, intradermal immunization schedule
is shown in figure 4. The distribution of the titers of
antisera produced in 128 rabbits is shown in figure 5.
Characterization of Antisera
Titer
The titer is defined as the antiserum dilution at which
50% of a given amount of labelled steroid is bound (25)
(figure 6). The assay conditions used to assess the titer
of an antiserum must be held constant in order to com-
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Fig. 5. Distribution (%) of antiserum titers produced iri 128
rabbits after one-time, multiple site, intradermal immuni-
















Ι ι ι ι
1/1,000 1/4,000 1/16,000 1/64,000 1/256,000
1/2,000 1/8jOOO V32,000 1/128,000
Antiserum di lut ion
Fig. 4. Development of antiserum titers in 8 male rabbits
immunized against testosterone
Fig. 6. Determination of antiserum titer
monitor changing antiserum levels in one animal. The
conditions used are therefore similar to those of the
final assay system.
When establishing the assay conditions,'the titer is used
as the working dilution of the antiserum and can be
adjusted later for optimization of the assay. If antisera
from different animals or from several bleedings of one
animal are available, the antiserum with the highest
titer is usually selected for the assay. In published assay
methods, the antiserum titers range fronv'1/5,000 to
1/100,000. Few assays have been reported using titers
exceeding 1/100,000 or below 1/1,000.
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Note that the titer of the antiserum is not necessarily
proportional to the antibody concentration (it is,
however, proportional to the product of the antibody
concentration and the affinity constant (Ka) (26)), nor
does the titer give any indication of the specificity of
the antiserum.Φ
Affinity
The binding affinity of the antibody towards the steroid
hapten governs the sensitivity and detection limit of
the assay (2, 25). The affinity constant can be calculated
from either a Scatcliard plot (27) or from Michaelis·
Menten curves (28). In the second approach the sat-
uration data used in the calculation gives an average
affinity constant for the total heterogeneous population
of antibody binding sites, while Scatchard plots give an
indication of the number of antibody populations
present. The Ka constant is defined in the Michaelis·
Menten method as the reciprocal of the free (unbound)
steroid molar concentration at half saturation of the
antibody binding sites (figures 7 and 8).
Binding affinities calculated for populations of steroid
antibodies are of the order of 109 1/mol and are thus
about 100-fold higher than the affinities of the specific
binding proteins, such as transcortin and testosterone-
binding globulin, but are in the same range as the bin-
ding affinities of the cellular steroid receptors.
The sensitivity (s) of an assay is usually taken to be one
tenth of the reciprocal of the binding affinity of the
average antibody population present:
0.1
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Testosterone bound [nmol / l ]
Fig. 7. Scatchard plot for calculation of antiserum binding
affinity, as exemplified by a testosterone antiserum,
diluted 1/25,000.
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Fig. 8. Michaelis-Meriten plot for calculation of antiserum
binding affinity
Specificity
Specificity depends on the degree of cross reaction of
the antiserum with other steroids, and is the most
important quality of the antiserum. This cross reaction
directly determines the overall specificity of a radio-
immunoassay in which the antiserum is used, and indi-
cates the extent to which the samples must be purified
before being assayed. Since the Chromatographie separa-
tion of one steroid from a sample is the rate-limiting
factor in the radioimmunoassay, the specificity of the
antiserum also dictates the practicability and final cost
of the assay.
The specificity of the antiserum is established by dis-
placement studies. The cross reaction is calculated from
the ratio of the mass of immunogenic steroid (x)
required to displace 50% of the radiolabelled immuno-
genic steroid to the mass of the cross reacting steroid
required to displace the same fraction of the labelled
steroid (y):
Cross Reaction = -
y
100%.
The factors governing specificity of an antiserum are
not fully understood. While one cannot determine
which part of the conjugate will act as the immuno-
determinant site, it was soon recognized that resulting
antisera were "far-sighted" (30, 31, 32, 33). That is,
steroid antisera are specific for the part of the steroid
moiety furthest from the site of conjugation to the
carrier. Thus if the steroid is coupled through ring D,
configurations on ring A are recognized; while antisera
against steroids coupled through position 3 (ring A)
show the opposite properties and ring D is recognized.
Since steroids are characterized by a specific pattern of
reactive oxygen functions, located mainly on the A and
D rings of the skeleton, antisera of enhanced specificity
have been produced against steroids coupled via the B
and C rings. This leaves both the immunodetermmant
Z. Klin. Chem. Klin. Biochem. / 13. Jahrg. 1975 / Heft 7 20 A
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Tab. 4. Specificity of antiscra raised against different estrogen
conjugates, expressed as percent cross reaction















sites available for antibody formation. The best example
of this type of coupling is 6-oxo-oestradiol-bovine
serum albumin (16, 34, 35, 36, 37) (tab. 4). This does
not apply to all steroids. The specificity of the antisera'
raised against testosterone conjugated through ring B
and C is only marginally better than that of antisera
raised against testosterone-3-bovine serum albumin
(tab. 5). In all these antisera a relatively high cross
reactivity to dihydrotestosterone is demonstrated.
It may be possible to elicit a more specific antibody
response by interposing a chemical "arm" between the
steroid and the'protein carrier (38). This is thought to
keep the hapten sufficiently distant from the carrier to
retain its identity, which may otherwise be masked by
steric interactions with the protein molecule. The recent
synthesis of oligomeric steroid derivatives may also be
an effective means of eliciting specific antibody for-
mation (39).
Affinity chromatogfaphy and gel filtration techniques
have also been used to increase the specificity of exi-
sting antibody preparations, by removing the popul-
ations of low affinity antibodies (40, 41, 42).
Labelled Steroids
Either |3- or γ-emitting radiolabelled steroids can be
used in radioimmunoassays. Tritiated steroids are
usually the first choice, as they are readily available
commercially. Such labelled steroids have a relatively
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high specific activity, with the radiolabel incorporated
in the skeleton at one, two or four positions eg. [7-3H]
dehydroepiandrosterone; [1,2-3H] testosterone; [1, 2,
6, 7-3H] testosterone. These highly labelled steroids
are stable for periods of longer than onfe year, provided
they are purified regularly to remove radiation damaged
material.
The inclusion of a radioactive atom in the steroid
skeleton had been thought to result in a difference in '
the binding kinetics between the radioactive and non-
radioactive steroid (43). However, such an isotope
effect has not been demonstrated with 3H- or 14C-
labelled steroids.(44).
The counting of /J-emitting isotopes necessitates the use
of scintillation media, and hence /3-counting is more
expensive and more time-consuming than γ-counting.
For this reason, some workers have chosen to use
iodinated steroid conjugates. With the exception of the
phenolic A ring of the natural estrogens, it is not
possible to iodinate the cyclopentanoperhydrophen-
anthrene nucleus or its substituents directly (45).
However, it is possible to introduce the radiolabel on a
carrier protein in a similar manner to that of the
steroid-protein conjugate (32). This would give the
iodinated steroid conjugate approximately the same
configuration as the immunogen, but its structure would
be very different from the unknown or standard steroid
preparation. It is possible to prepare steroid derivatives
where only one iodine atom is introduced per conjugate.
The steroid is coupled to the methyl ester of tyrosine,
which is then used for iodination (46, 47); histamine
can be used as an alternative carrier (48). One argument
against the use.of iodine labels in steroid radioimmuno-
assays is the size of the iodine atom, which is greater
than the A ring configuration of the skeleton. The intro-
duction of such a large atom also affects the kinetics of
binding between the labelled antigen and antibody.
Smaller γ-emitting atoms, such as 75selenium, may
therefore be of advantage. 75Selenium steroid conju-
gates of cortisol, testosterone and aldosterone have been
Tab. 5. Specificity of antisera raised against different testosterone conjugates, expressed as percent cross reaction
(T = testosterone, 5a-DHT = 5a-dihydrotestosterone, BSA = bovine serum albumin), nr = not recorded.
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prepared, and the use of 75Se-cortisol in a competitive
binding assay has been described (49).
Assay Procedure
Deproteinizat ion
Unlike protein hormones, which can be assayed in un-
processed samples, steroid samples must be purified
prior to assay. The steroid-binding proteins must be
removed, since these compete with the antibody binding
sites for the free steroid. Such deproteinization is usu-
ally accomplished by solvent partition. The choice of
solvent and its degree of purity are important, since a
non-specific blank contribution can arise from this step.
The following solvents have been applied to the extrac-
tion of steroids (tab. 6).
Separation of Cross-Reacting Steroids
With regard to specificity, practicability and cost, the
most important question is whether a Chromatographie
separation is included in the radioimmunoassay, or not.
The specificity of the antiserum gives a strong indication
of this. Where such a Chromatographie step can be
avoided, the practicability of the assay is markedly
increased and the cost per assay can be correspondingly
reduced.
The most commonly used Chromatographie systems and
an indication of their frequency are given in table 7.
Of these systems, partition and adsorption phase paper
chromatography have been widely investigated (50), but
since such methods are laborious and time-consuming,
they tend to have been abandoned in favor of other
methods. Column systems have the advantage that
they can be re-used after washing with solvent. However,
the technician may be overexposed to organic vapors, as
many systems using LH-Sephadex columns are benzene-
based. Complete separation of steroids with similar
polarities is difficult without some chemical transfor-
mation (51). Thin-layer chromatography is the most po-
pular technique, since total separations can be obtained
by varying the solvent composition with shortened
running times. The availability of commercially pre-
Tab. 6. Solvents used for extraction of steroids from body fluids
Tab. 7. Frequency of various Chromatographie methods in steroid
radio immunoassays
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pared plates with a variety of support media has led to
the standardization of such techniques and reproduci-
bility can be guaranteed.
If Chromatographie separation is necessary, it offers
the advantage that several steroids can be assayed
simultaneously in the same sample. All commonly used
chromatography systems can be adapted for this pur-
pose (69, 73, 77, 113, 117).
Separation of Bound and Free Steroids
The separation of antibody-bound and free steroid is
another rate-limiting step in the radioimmunoassay of
steroids. It influences the number of tubes which can be
handled per time unit, the reliability criteria and the
costs of the assay. The various methods in common use
are shown in table 8.
These data show that dextran-coated charcoal is widely
used (66%) and appears to be applicable to most steroids.
This method has the major disadvantage that the reaction
is time-dependent (52). More assay tubes can be handled
in a given time with separation techniques which are
independent of time. In this respect precipitation of
the bound fraction with saturated ammonium sulfate
solution appears to be the most widely used (20%). The
easiest and fastest separation techniques seem to be the
solid-phase systems such as antibody-coated tubes or
antibodies incorporated into polyacrylamide particles
(53, 62, 72, 75, 76). Some researchers have experienced
a loss of sensitivity using these techniques, which may
have prevented their wider application to date. The
solid phase methods have the disadvantage that large
amounts of antibody are required for the preparation of
Z. Klin. Chem. Klin. Biochem. / 13. Jahrg. 1975 / Heft 7 20 A*
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Tab. 8. Methods for separation of bound and free steroid
(Data from 70 randomly selected publications 1969-
1974)
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the media. The.use of a second antibody linked to a
solid matrix (eg. DASP), which has recently become
available commercially, promises to be of value in the
future (54, 55).
The immunosorbents developed for the separation of
free and bound protein hormones have also been
successfully applied to steroid assays (56, 57). In this
method, the first antibody is coupled to dextran par-
ticles, so that after equilibration bound and free steroid
can be separated by simple centrifugation.
Evaluation of Results
The evaluation of data from radioimmunoassay methods
is not a problem specific to steroid assays, and therefore
the reader is referred to general reviews of radioimmuno-
assays for the discussion of this topic (58, 59). As there
is no species specificity for steroid hormones, the radio-
immunoassay method should be applicable to any bio-
logical specimen from any species. However, the speci-
ficity of the assay may vary in the different types of
specimens, and hence should be checked in each indi-
vidual case.
Several approaches have been used to evaluate the
radioimmunoassay results, and to express the relation-
ship between the mass of steroid and the effect of bound
and/or free labelled steroid in the assay. These include
the linear logit-log transformation ofFeldman &Rodbard
(27) and the computer models of Wildman &Powsner
(60), and Rodbard &Lewald (61). There is, however,
no single way of expressing radioimmunoassay data,
since the shape of the standard curve depends on the
affinity constant and heterogeneity of the antiserum
used. Any computer program used must therefore be
capable of forming a "best fit" curve to the data, and
not vice vsrsa, to be applicable for all types of antisera.
Factors Affecting Assay Design - Reliability Criteria
The type of steroid-conjugates used for immunization
and the hydrophobic character of the steroid haptens
account for some of the properties peculiar to steroid
radioimmunoassays. These properties include the
apparently smaller affinity constants obtained for
steroid antisera over protein antisera; the high associ-
ation and dissociation constants of the steroid-antibody
reaction; the spectrum of antibody affinities present
and the effect of non-polar substances on the steroid^
antibody reaction.
Assay Sensitivity
Two types of sensitivity can be evaluated, that of the
standard curve and that of the overall assay, The first
depends on the affinity of the antiserum, the mass of
antibody and labelled tracer used in the assay, the
volume of the incubation media (since the affinity
constant is defined in terms of mass/volume) and the
error (and hence precision) of the method. The assay
sensitivity depends on the sensitivity of the standard
curve (indicated by its slope), the blank value of the
assay and the recovery of steroid after any purification
procedures.
Several factors of assay procedure can be varied to
optimize the overall sensitivity.
Assay Blanks
Many of the factors contributing to the method blank
are purely chemical and may therefore be avoided.
The affinity constant of the antiserum influences the
blank value, with a low affinity causing an increase in
the blank contribution. The buffer system used may
affect the antigen-antibody reaction, causing an alter-
ation in the shape of the standard curve. Addition of
proteins to the incubation media, such as bovine
serum albumin, γ-globulin or gelatin to prevent the
adsorption of steroids to the tube walls, and increasing -
the ionic strength of dilute solutions by salt addition
can effectively reduce the blank contribution (25, 38).
Reagents may also make a significant contribution to
the apparent hormone level measured. This is especially
important when Chromatographie techniques are inclii-
..ded in the method, as the support medium may also
contribute significantly to this effect. The reagent
blank is not always reduced by using redistilled and
high-grade products.
The susceptibility of steroid antisera to the interference
of non-polar substances, such as dried residues of organic
solvents and lipophilic substances, is due to the influence
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of these factors on the hydrophobia steroid-antibody
interaction. Coextraction of lipids from plasma may
therefore impede the direct assay of crude extracts,
even when highly specific antisera are used.
The means of separation of free and bound steroid may
also cause a significant blank problem. The use of solid-
phase systems has been criticized because of the loss of
sensitivity resulting from increased blank contributions.
Incubation Environment
Under normal conditions of assay, the steroid-antibody
reaction reaches apparent equilibrium after a relatively
short time (1—4 hours at room temperature). The
problem of non-equilibrium conditions therefore rarely
occurs in steroid radioimmunoassays.
The antigen-antibody complex is stable over a wide pH
range, and small changes in the pH of the incubation
media have little effect on the formation of the complex.
However, the stability is radically affected by the disso-
ciating action of adsorbants such as charcoal. There is
a progressive dissociation of the complex with increas-
ing amounts of charcoal and increasing incubation
time.
The presence of a heterogeneous population of antibody
binding sites can also be demonstrated by the different
rates of dissociation of the steroid-antibody complexes
present in the incubation medium. The use of charcoal
and dextran-coated charcoal, although a very convenient
means of separating the free and bound steroid, requires
the careful optimization of experimental conditions (in
terms of amount of adsorbent added, length of incu-
bation time, etc.) to counterbalance the dissociation
effects within the same set of tubes.
Other factors to be considered regarding the acceptabi-
lity of a steroid radioimmunoassay include accuracy,
precision, specificity and finally, practicability.
Accuracy
The accuracy is determined by performing recovery
experiments whereby increasing amounts of the steroid
are added to plasma aliquots, and the level of steroid
present is assayed. A correlation coefficient of 1.00
should be obtained, but deviations may be caused by
methodological and personal errors.
Precision
The repeated measurement of a sample in the same assay,
and in successive different assays, will give an estimation
of the intra- and inter-assay variation. The acceptability
of an assay in terms of its precision must be carefully
considered, if the ass^y is to be used to measure steroid
levels in the same subjects over a prolonged period of time.
The data generally reported in recent publications show
a coefficient of variation of about 10% for intra-assay
precision, and up to 15% for inter-assay precision.
Specificity
This can be demonstrated in two ways: first, that
steroids present in the purified fraction in which the
specific steroid is contained do not interfere in the
assay either because of low cross reactivity with the
antiserum, or because they are present in comparatively
small amounts; secondly, that levels of a steroid meas-
ured by radioimmunoassay correlate well with the
corresponding levels measured by alternative techniques.
Practicability
This is judged according to the degree of skill required
in the manipulation of the assay, and also its cost.
Hence the inclusion of a Chromatographie purification
step may be "impractical" in these terms although
necessary for increased specificity. Many steroid assays
have become more practical as increased use is made of
automated techniques. However, the cost of the equip-
ment needed for such steps is the limiting factor in their
application to steroid assays.
Conclusions
In the last five years radioimmunoassay has almost com-
pletely conquered the field of steroid analysis and has
made obsolete almost all previously used techniques
for routine analysis. Radioimmunoassay can be applied
to most forms of biological material, such as blood,
urine and tissue preparations. It is possible to automate
at least parts of the assay procedures, and calculation
of the results by computer facilitates the handling of
large numbers of samples simultaneously. With the
inclusion of a Chromatographie step several steroids may
be measured simultaneously in small sample volumes.
The required plasma volumes are also small enough to
allow for frequent sampling in the same patient when
hormone profiles and rapid fluctuations should be meas-
ured. The assays offer satisfactory reliability and the
sensitivity is sufficient for many current medical
problems. Further improvements can be expected from
the development of antisera showing a lesser degree of
cross reaction with other steroids.
In the enthusiasm for radioimmunoassay, however,
other methods should not be overlooked. The use of
mass spectrometry is extremely valuable as a reference
method because it offers absolute specificity. Further-
more, radioimmunoassay will always require separation
of antibody-bound and free hormone, which will cause
problems in the full automation of the assays. This will
be necessary in large routine laboratories and for
screening programs in preventive medicine. In addition,
the counting of radioactivity is expensive and time-
consuming. Therefore alternative methods are awaited
with great interest. Of the recent developments, enzyme-
immunoassays, where the radiolabel is replaced by an
enzyme, appear to overcome some of the problems of
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radioimmunoassays. Since in these assays the end-point
determination will not be the counting of radioactivity
but spectrophotometry, enzyme-immunoassays could be
introduced into all clinical chemistry laboratories which
had been prevented from using radioimmunoassays
because of the high costs of counting equipment. Thus,
in connection with newly developed antisera showing
negligible cross reaction with other steroids, enzyme-
immunoassays could offer a suitable alternative to
radioimmunoassay in the future.
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